GEN Exclusives

More »

GEN News Highlights

More »
Oct 7, 2008

Takeda Pays Alnylam $20M upon Technology Transfer

  • Alnylam Pharmaceuticals achieved a $20 million technology transfer milestone from Takeda Pharmaceutical Company (as per the agreement formed between the companies in May 2008). This payment is related to the transfer of Alnylam's platform technology including documents, materials, and know-how to Takeda for the development of RNAi therapeutics.

    Alnylam received an initial payment of $100 million and stands to earn another $30 million as a technology transfer milestone fee in the near term. The strategic alliance formed between the firms is valued at over $1 billion in milestones related to R&D and commercialization.

    Besides gaining access to Alnylam’s RNAi technology platform for immediate use in oncology and metabolic disorders, Takeda also became the company’s Asian partner for RNAi therapeutics for the next five years.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »